Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Meeting ReportMolecular Targeting Probes - Radioactive & Nonradioactive

Design of calcium-sensing receptor targeted thera(g)nostic agents

Xiaonan Deng, Weiping Yu, Mingyong Li, Cassandra Miller, Yao Xin, Matthew Goodman, Jian Hu, Mark Goodman and Jenny Yang
Journal of Nuclear Medicine May 2020, 61 (supplement 1) 618;
Xiaonan Deng
1Chemistry Georgia State University Atlanta GA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Weiping Yu
2Emory University Atlanta GA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mingyong Li
3Shandong University Jinan China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cassandra Miller
1Chemistry Georgia State University Atlanta GA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yao Xin
1Chemistry Georgia State University Atlanta GA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew Goodman
1Chemistry Georgia State University Atlanta GA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jian Hu
4Michigan State University East Lansing MI United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Goodman
2Emory University Atlanta GA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jenny Yang
1Chemistry Georgia State University Atlanta GA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

618

Objectives: The Ca2+-sensing receptor (CaSR) plays a central role in regulating [Ca2+]o homeostasis and many (patho)physiological processes in multiple organs. Numerous diseases are related to mishandling calcium such as familial hypocalciuric hypercalcemia (FHH), neonatal severe hyperparathyroidism (NSHPT), autosomal dominant hypocalcemia (ADH), autosomal dominant hypocalcemic hypercalciuria (ADHH), renal stone disease (nephrolithiasis) and secondary hyperparathyroidism (HPT) by chronic kidney disease (CKD). Therefore, it is critical to develop novel allosteric modulators for various diseases with cellular and organ specificity as well as mapping CaSR in vivo expression and preoperative or intraoperative imaging. Here, we report our effort in the design of a novel class of calcium-sensing receptor-targeted thera(g)nostic agents.

Methods: High-resolution X-ray crystallography was applied to determine the structure of the extracellular domain of calcium-sensing receptor that was mammalian cell expressed, deglycosylated and purified. Mass spectrometry was applied to identify a tryptophan derivative (TNCA) that is co-crystalized with the ECD of CaSR. Functional assay, computational modeling, and docking were further performed to design an array of drug candidates. The binding affinity of synthesized tetrahydro-beta-carblinecarboxylic acids including [18F] (1) was determined and their efficacies to CASR were examined by an array of functional assays. [18F] (1) was synthesized and whole body MicroPET-CT images will be performed in rats to examine the biodistribution of CaSR in vivo. The histological analysis of (1) will be performed to determine the targeting specificity of the TNCA agent to CaSR with IHC and IFC.

Results: We have determined the first crystal structure of the human CaSR extracellular domain (ECD) with bound Mg2+ and identified a novel agonist tryptophan derivative (TNCA) at 2.1 Å. We have further synthesized compound (1) based on structural modeling and docking of the CaSR-TNCA complex. (1) was shown to have significantly improved potency and efficacy (>1000 fold) to CASR mediated calcium oscillation and IP production than natural amino acid Phe. (1) is also able to rescue cellular functions of CASR with disease mutations. The binding of (1) to CaSR has been further determined by FRET assay and radioactive binding assay. Its 19F (1) was further shown to has strong agonist activity and specificity to CaSR using CaSR stably transfected cell line. PET imaging and histological analysis indicate this derivative also has strong in vivo CaSR targeting specificity and sensitivity.

Conclusions: We have shown our hypothesis that effective thera(g)nostic agonists of CaSR can be achieved by the development of 18F/19F derivatives of TNCA with strong affinity, specificity, and proper in vivo organ and tissue distribution. We have demonstrated a novel avenue in the development of CaSR specific agonists and antagonists for imaging and the treatment of various CaSR associated human diseases using newly available structures and patented methodology. Acknowledgment: This work was supported in part by NIH Research Grants R33CA235319, R42CA183376, R42AA025863 and American Heart Association 16GRNT31210016 to JJY

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 61, Issue supplement 1
May 1, 2020
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Design of calcium-sensing receptor targeted thera(g)nostic agents
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Design of calcium-sensing receptor targeted thera(g)nostic agents
Xiaonan Deng, Weiping Yu, Mingyong Li, Cassandra Miller, Yao Xin, Matthew Goodman, Jian Hu, Mark Goodman, Jenny Yang
Journal of Nuclear Medicine May 2020, 61 (supplement 1) 618;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Design of calcium-sensing receptor targeted thera(g)nostic agents
Xiaonan Deng, Weiping Yu, Mingyong Li, Cassandra Miller, Yao Xin, Matthew Goodman, Jian Hu, Mark Goodman, Jenny Yang
Journal of Nuclear Medicine May 2020, 61 (supplement 1) 618;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Molecular Targeting Probes - Radioactive & Nonradioactive

  • In vitro response of 177Lu-PSMA-617 with two different specific activities
  • ‘In-loop’ [11C]CO2fixation: Application to the synthesis of a 11C-labeled cholesterol 24-hydroxylase inhibitor
  • A Unique 18F-labeled G-protein-coupled receptor 44 (GPR44) radiotracer: design, radio-synthesis and evaluation in the rodents
Show more Molecular Targeting Probes - Radioactive & Nonradioactive

New Radiotracers

  • Syntheses of [11C]2- and [11C]3-trifluoromethyl-4-aminopyridine: potential PET radioligands for imaging demyelinating diseases
  • In vitro response of 177Lu-PSMA-617 with two different specific activities
  • SPECT and PET imaging of CD11b-positive immune cells in an orthotopic mouse model of glioma with Zr-89 and Lu-177 labeled Lumi804-anti-CD11b antibody
Show more New Radiotracers

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire